Curasight’s CEO Ulrich Krasilnikoff comments:

"Throughout the first three quarters of 2024, we have built upon last year’s successes, fortifying Curasight’s role in radiopharmaceuticals. Key milestones include enrolling our first patient in the Phase II trial of uTRACE for prostate cancer and furthering our partnership with Curium, where we received a second milestone payment under the collaboration. Additionally, we announced a capital raise designed to enhance our financial position, and extending our cash runway well into the latter half of 2025."

Q3 (2024-07-01 – 2024-09-30)

• Gross loss amounted to kDKK -6,135 (kDKK –6,551)
• Operating loss amounted to kDKK -8,099 (kDKK -8,465)
• Loss before tax amounted to kDKK -8,523 (kDKK -8,484)
• Loss for the period amounted to kDKK -7,148 (kDKK -6,618)
• Total assets amounted to kDKK 25,778 (kDKK 41,913)
• Equity ratio amounted to 51.6% (90.1%)
• Earnings per share amounted to DKK -0.35 (DKK -0.33)

Q1-Q3 (2024-01-01 – 2024-09-30)

• Gross loss amounted to kDKK -22,521 (kDKK –20,236)
• Operating loss amounted to kDKK -28,443 (kDKK -25,307)
• Loss before tax amounted to kDKK -30,002 (kDKK -25,328)
• Loss for the period amounted to kDKK -25,877 (kDKK -19,756)
• Total assets amounted to kDKK 25,778 (kDKK 41,913)
• Equity ratio amounted to 51.6% (90.1%)
• Earnings per share amounted to DKK -1.25 (DKK -0.99)

Numbers in parenthesis are the numbers from the same period in 2023.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE^®) and Radioligand Therapy (uTREAT^®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.